Chinese General Practice ›› 2024, Vol. 27 ›› Issue (18): 2179-2185.DOI: 10.12114/j.issn.1007-9572.2023.0892
Special Issue: 心力衰竭最新文章合辑
• Article • Previous Articles Next Articles
Received:
2024-01-17
Revised:
2024-02-28
Published:
2024-06-20
Online:
2024-03-22
Contact:
JIAN Liguo
通讯作者:
简立国
作者简介:
基金资助:
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0892
组别 | 例数 | 年龄[M(P25,P75),岁] | 性别[例(%)] | 入院心率[M(P25,P75),次/min] | BMI[M(P25,P75),kg/m2] | SBP( | DBP[M(P25,P75),mmHg] | FBG[M(P25,P75),mmol/L] | TG[M(P25,P75),mmol/L] | |
---|---|---|---|---|---|---|---|---|---|---|
女 | 男 | |||||||||
对照组 | 252 | 67.0(57.0,76.0) | 102(40.5) | 150(59.5) | 74.0(68.0,83.8) | 23.9(22.0,26.4) | 126±18 | 75(68,85) | 5.1(4.6,5.9) | 1.2(0.9,1.5) |
全因死亡组 | 61 | 78.0(68.0,84.5) | 27(44.3) | 34(55.7) | 80.0(66.5,90.0) | 25.3(22.2,28.1) | 127±19 | 74(66,82) | 5.5(4.6,8.4) | 1.0(0.8,1.3) |
检验统计量值 | 5.255 | 0.291a | 1.521 | 2.418 | 0.285b | 1.041 | 1.983 | 2.162 | ||
P值 | <0.001 | 0.590 | 0.128 | 0.016 | 0.776 | 0.298 | 0.047 | 0.031 | ||
组别 | HDL-C[M(P25,P75),mmol/L] | TC[M(P25,P75),mmol/L] | LDL-C[M(P25,P75),mmol/L] | Mets-IR[M(P25,P75)] | NT-proBNP[M(P25,P75),pg/mL] | ALB[M(P25,P75),g/L] | AST[M(P25,P75),U/L] | ALT[M(P25,P75),U/L] | Scr[M(P25,P75),μmol/L] | BUN[M(P25,P75),mmol/L] |
对照组 | 1.0(0.9,1.3) | 3.4(3.0,4.1) | 2.2(1.6,2.7) | 36.4(33.2,41.3) | 2 715(1 642,6 250) | 40.6(37.7,43.6) | 24.0(18.0,33.8) | 22.0(15.0,34.8) | 82.0(67.3,98.8) | 6.4(5.2,8.5) |
全因死亡组 | 0.9(0.7,1.1) | 3.3(2.8,4.1) | 1.9(1.5,2.5) | 40.8(36.8,45.8) | 5 412(2 710,13 350) | 37.0(32.8,40.0) | 28.0(17.5,39.5) | 24.0(11.5,37.0) | 85.0(70.0,105.0) | 7.1(5.3,8.5) |
检验统计量值 | 3.722 | 0.957 | 1.995 | 4.468 | 3.737 | 5.685 | 1.304 | 0.146 | 0.994 | 0.480 |
P值 | <0.001 | 0.339 | 0.046 | <0.001 | <0.001 | <0.001 | 0.192 | 0.884 | 0.320 | 0.631 |
组别 | SUA[M(P25,P75),μmol/L] | 中性粒细胞计数[M(P25,P75),×109/L] | RDW[M(P25,P75),%] | HB[M(P25,P75),g/L] | 血Na[M(P25,P75),mmol/L] | 血K[M(P25,P75),mmol/L] | LVEF[M(P25,P75),%] | LVEDD[M(P25,P75),mm] | AF[例(%)] | |
无 | 有 | |||||||||
对照组 | 361.0(289.5,457.8) | 4.3(3.4,5.6) | 13.3(12.7,14.3) | 126.0(113.0,139.8) | 139.0(137.0,141.0) | 4.2(3.8,4.5) | 48.0(40.3,56.0) | 49.0(44.0,57.0) | 191(75.8) | 61(24.2) |
全因死亡组 | 403.0(319.0,559.5) | 5.0(3.9,7.2) | 13.9(13.2,15.4) | 117.0(96.0,134.5) | 138.0(134.0,140.5) | 4.2(3.7,4.6) | 41.0(37.0,45.0) | 52.0(43.5,60.5) | 36(59.0) | 25(41.0) |
检验统计量值 | 2.236 | 2.117 | 4.051 | 2.767 | 2.899 | 0.142 | 5.438 | 1.012 | 6.937a | |
P值 | 0.025 | 0.034 | <0.001 | 0.006 | 0.004 | 0.887 | <0.001 | 0.311 | 0.008 | |
组别 | CAD[例(%)] | 糖尿病[例(%)] | 高血压[例(%)] | 吸烟史[例(%)] | ACEI/ARB/ARNI[例(%)] | |||||
无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | |
对照组 | 111(44.0) | 141(56.0) | 186(73.8) | 66(26.2) | 129(51.2) | 123(48.8) | 175(69.4) | 77(30.6) | 84(33.3) | 168(66.7) |
全因死亡组 | 24(39.3) | 37(60.7) | 43(70.5) | 18(29.5) | 21(34.4) | 40(65.6) | 45(73.8) | 16(26.2) | 32(52.5) | 29(47.5) |
检验统计量值 | 0.443a | 0.275a | 5.530a | 0.440a | 7.702a | |||||
P值 | 0.506 | 0.600 | 0.019 | 0.507 | 0.006 | |||||
组别 | β受体阻滞剂[例(%)] | 利尿剂[例(%)] | 醛固酮受体拮抗剂[例(%)] | 降脂药[例(%)] | NYHA分级[例(%)] | |||||
无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | Ⅰ、Ⅱ级 | Ⅲ、Ⅳ级 | |
对照组 | 46(18.3) | 206(81.7) | 47(18.7) | 205(81.3) | 94(37.3) | 158(62.7) | 69(27.4) | 183(72.6) | 69(27.4) | 183(72.6) |
全因死亡组 | 12(19.7) | 49(80.3) | 2(3.3) | 59(96.7) | 11(18.0) | 50(82.0) | 22(36.1) | 39(63.9) | 5(8.2) | 56(91.8) |
检验统计量值 | 0.065a | 8.789a | 8.180a | 1.796a | 10.012a | |||||
P值 | 0.798 | 0.003 | 0.004 | 0.180 | 0.002 |
Table 1 Comparison of baseline data between the two groups
组别 | 例数 | 年龄[M(P25,P75),岁] | 性别[例(%)] | 入院心率[M(P25,P75),次/min] | BMI[M(P25,P75),kg/m2] | SBP( | DBP[M(P25,P75),mmHg] | FBG[M(P25,P75),mmol/L] | TG[M(P25,P75),mmol/L] | |
---|---|---|---|---|---|---|---|---|---|---|
女 | 男 | |||||||||
对照组 | 252 | 67.0(57.0,76.0) | 102(40.5) | 150(59.5) | 74.0(68.0,83.8) | 23.9(22.0,26.4) | 126±18 | 75(68,85) | 5.1(4.6,5.9) | 1.2(0.9,1.5) |
全因死亡组 | 61 | 78.0(68.0,84.5) | 27(44.3) | 34(55.7) | 80.0(66.5,90.0) | 25.3(22.2,28.1) | 127±19 | 74(66,82) | 5.5(4.6,8.4) | 1.0(0.8,1.3) |
检验统计量值 | 5.255 | 0.291a | 1.521 | 2.418 | 0.285b | 1.041 | 1.983 | 2.162 | ||
P值 | <0.001 | 0.590 | 0.128 | 0.016 | 0.776 | 0.298 | 0.047 | 0.031 | ||
组别 | HDL-C[M(P25,P75),mmol/L] | TC[M(P25,P75),mmol/L] | LDL-C[M(P25,P75),mmol/L] | Mets-IR[M(P25,P75)] | NT-proBNP[M(P25,P75),pg/mL] | ALB[M(P25,P75),g/L] | AST[M(P25,P75),U/L] | ALT[M(P25,P75),U/L] | Scr[M(P25,P75),μmol/L] | BUN[M(P25,P75),mmol/L] |
对照组 | 1.0(0.9,1.3) | 3.4(3.0,4.1) | 2.2(1.6,2.7) | 36.4(33.2,41.3) | 2 715(1 642,6 250) | 40.6(37.7,43.6) | 24.0(18.0,33.8) | 22.0(15.0,34.8) | 82.0(67.3,98.8) | 6.4(5.2,8.5) |
全因死亡组 | 0.9(0.7,1.1) | 3.3(2.8,4.1) | 1.9(1.5,2.5) | 40.8(36.8,45.8) | 5 412(2 710,13 350) | 37.0(32.8,40.0) | 28.0(17.5,39.5) | 24.0(11.5,37.0) | 85.0(70.0,105.0) | 7.1(5.3,8.5) |
检验统计量值 | 3.722 | 0.957 | 1.995 | 4.468 | 3.737 | 5.685 | 1.304 | 0.146 | 0.994 | 0.480 |
P值 | <0.001 | 0.339 | 0.046 | <0.001 | <0.001 | <0.001 | 0.192 | 0.884 | 0.320 | 0.631 |
组别 | SUA[M(P25,P75),μmol/L] | 中性粒细胞计数[M(P25,P75),×109/L] | RDW[M(P25,P75),%] | HB[M(P25,P75),g/L] | 血Na[M(P25,P75),mmol/L] | 血K[M(P25,P75),mmol/L] | LVEF[M(P25,P75),%] | LVEDD[M(P25,P75),mm] | AF[例(%)] | |
无 | 有 | |||||||||
对照组 | 361.0(289.5,457.8) | 4.3(3.4,5.6) | 13.3(12.7,14.3) | 126.0(113.0,139.8) | 139.0(137.0,141.0) | 4.2(3.8,4.5) | 48.0(40.3,56.0) | 49.0(44.0,57.0) | 191(75.8) | 61(24.2) |
全因死亡组 | 403.0(319.0,559.5) | 5.0(3.9,7.2) | 13.9(13.2,15.4) | 117.0(96.0,134.5) | 138.0(134.0,140.5) | 4.2(3.7,4.6) | 41.0(37.0,45.0) | 52.0(43.5,60.5) | 36(59.0) | 25(41.0) |
检验统计量值 | 2.236 | 2.117 | 4.051 | 2.767 | 2.899 | 0.142 | 5.438 | 1.012 | 6.937a | |
P值 | 0.025 | 0.034 | <0.001 | 0.006 | 0.004 | 0.887 | <0.001 | 0.311 | 0.008 | |
组别 | CAD[例(%)] | 糖尿病[例(%)] | 高血压[例(%)] | 吸烟史[例(%)] | ACEI/ARB/ARNI[例(%)] | |||||
无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | |
对照组 | 111(44.0) | 141(56.0) | 186(73.8) | 66(26.2) | 129(51.2) | 123(48.8) | 175(69.4) | 77(30.6) | 84(33.3) | 168(66.7) |
全因死亡组 | 24(39.3) | 37(60.7) | 43(70.5) | 18(29.5) | 21(34.4) | 40(65.6) | 45(73.8) | 16(26.2) | 32(52.5) | 29(47.5) |
检验统计量值 | 0.443a | 0.275a | 5.530a | 0.440a | 7.702a | |||||
P值 | 0.506 | 0.600 | 0.019 | 0.507 | 0.006 | |||||
组别 | β受体阻滞剂[例(%)] | 利尿剂[例(%)] | 醛固酮受体拮抗剂[例(%)] | 降脂药[例(%)] | NYHA分级[例(%)] | |||||
无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | Ⅰ、Ⅱ级 | Ⅲ、Ⅳ级 | |
对照组 | 46(18.3) | 206(81.7) | 47(18.7) | 205(81.3) | 94(37.3) | 158(62.7) | 69(27.4) | 183(72.6) | 69(27.4) | 183(72.6) |
全因死亡组 | 12(19.7) | 49(80.3) | 2(3.3) | 59(96.7) | 11(18.0) | 50(82.0) | 22(36.1) | 39(63.9) | 5(8.2) | 56(91.8) |
检验统计量值 | 0.065a | 8.789a | 8.180a | 1.796a | 10.012a | |||||
P值 | 0.798 | 0.003 | 0.004 | 0.180 | 0.002 |
变量 | 未调整模型 | 模型1 | 模型2 | 模型3 | 模型4 | |||||
---|---|---|---|---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
高水平Mets-IR(以低水平Mets-IR为参照) | 3.23(1.82~5.71) | <0.001 | 3.19(1.80~5.65) | <0.001 | 2.74(1.50~5.02) | 0.001 | 2.83(1.50~5.35) | 0.001 | 2.90(1.51~5.54) | 0.001 |
Table 2 Cox proportional hazards regression analysis of Mets-IR affecting the risk of all-cause mortality
变量 | 未调整模型 | 模型1 | 模型2 | 模型3 | 模型4 | |||||
---|---|---|---|---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
高水平Mets-IR(以低水平Mets-IR为参照) | 3.23(1.82~5.71) | <0.001 | 3.19(1.80~5.65) | <0.001 | 2.74(1.50~5.02) | 0.001 | 2.83(1.50~5.35) | 0.001 | 2.90(1.51~5.54) | 0.001 |
变量 | 未调整模型 | 模型1 | 模型2 | 模型3 | 模型4 | |||||
---|---|---|---|---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
高水平Mets-IR(以低水平Mets-IR为参照) | 1.86(1.29~2.68) | 0.001 | 1.87(1.29~2.70) | 0.001 | 1.68(1.15~2.44) | 0.007 | 1.56(1.06~2.30) | 0.025 | 1.55(1.04~2.30) | 0.030 |
Table 3 Cox proportional hazards regression analysis of Mets-IR affecting the risk of readmission due to HF
变量 | 未调整模型 | 模型1 | 模型2 | 模型3 | 模型4 | |||||
---|---|---|---|---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
高水平Mets-IR(以低水平Mets-IR为参照) | 1.86(1.29~2.68) | 0.001 | 1.87(1.29~2.70) | 0.001 | 1.68(1.15~2.44) | 0.007 | 1.56(1.06~2.30) | 0.025 | 1.55(1.04~2.30) | 0.030 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):760-789. DOI:10.3760/cma.j.issn.0253-3758.2018.10.004.
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[1] | MA Shuangshuang, XING Yanjiang, ZHANG Jiawei, WANG Jing. Research Progress on Cardiac Energy Metabolic Changes in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2025, 28(30): 3831-3840. |
[2] | LIU Zhenyu, WEI Yunpeng, WANG Jiangmin, XING Yan. Causal Association Study between Sleep Duration and Heart Failure [J]. Chinese General Practice, 2025, 28(27): 3441-3446. |
[3] | LIU Wenjie, SUN Huang, LUO Wei, CHEN Xuan, PENG Yunzhu, LI Ruijie, MA Mier. Wearable Acoustic-electrocardiographic Remote Monitoring Device for Heart Failure [J]. Chinese General Practice, 2025, 28(25): 3104-3109. |
[4] | HAN Bing, DU Shuzhen, MENG Xiaoxue, ZHANG Lu, CHEN Zixian, TENG Fengling. Plasma Periostin Levels Correlated with Myocardial Fibrosis in Patients with Heart Failure with Different Ejection Fraction [J]. Chinese General Practice, 2025, 28(24): 2979-2984. |
[5] | YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058. |
[6] | DONG Haocheng, HAO Xiao, AN Dong, LI Haohan, LI Shuren. Research Progress of Heart Failure with Supra-normal Ejection Fraction [J]. Chinese General Practice, 2025, 28(21): 2692-2696. |
[7] | HE Ting, LI Jia, TAN Wenbin. Research Progress of Circulatory System Diseases and Secondary Osteoporosis [J]. Chinese General Practice, 2025, 28(17): 2101-2112. |
[8] | HUANG Chuanying, LIAO Xiaoyang, YANG Rong, LI Dongze, ZHANG Peng, JIA Yu, LIU Lidi. Interpretation of the Clinical Statement for Management of Female Cardiac Emergencies in 2024 [J]. Chinese General Practice, 2025, 28(12): 1427-1432. |
[9] | BAI Lu, ZHANG Qiang, LIU Fangfang, SUN Caihong, FEI Sijie, XIN Caifeng. Correlation between Triglyceride Glucose Index and Atrial Fibrillation in Patients with Chronic Heart Failure [J]. Chinese General Practice, 2025, 28(06): 720-728. |
[10] | LU Jing, SUN Guozhen, WANG Jie, GAO Min, YU Tianxi, SUN Shuyi, WANG Qin, WEN Gaoqin. Interpretable Analysis of Influencing Factors and the Current State of Social Frailty in Patients with Chronic Heart Failure [J]. Chinese General Practice, 2025, 28(02): 220-227. |
[11] | HUANG Kai, ZHANG Yi, YANG Chun, YANG Ling. Advances in Gut Microbiota in Heart Failure Combined with Depression [J]. Chinese General Practice, 2024, 27(35): 4455-4461. |
[12] | LIU Shenxinyu, GAO Min, WANG Jie, BAO Zhipeng, YU Tianxi, TANG Zhijie, SUN Shuyi, SUN Guozhen. Construction of a Service Quality Assessment Indicator System for Home-based Rehabilitation APP for Heart Failure Patients [J]. Chinese General Practice, 2024, 27(30): 3758-3762. |
[13] | ZHANG Jin, ZHANG Rui, CHI Jingjing, LI Ya, BAI Wenpei. Impact of LncRNA MALAT1 in the Placentas of Pre-pregnancy Overweight/Obese Women on Maternal and Infant Metabolism [J]. Chinese General Practice, 2024, 27(27): 3383-3387. |
[14] | WANG Wuchao, LIU Siqi, LIU Qianqian, ZHU Jihong. Clinical Characteristics of Acute Pulmonary Embolism Complicated with Thrombocytopenia: a Retrospective Study [J]. Chinese General Practice, 2024, 27(27): 3372-3377. |
[15] | CHEN Kejun, YANG Yifei, GONG Jing, YANG Binxu, ZHOU Jing. Application Progress of Electronic Health Technology in Home Management of Patients with Heart Failure [J]. Chinese General Practice, 2024, 27(26): 3212-3217. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||